Cell Genesys Showing New Positive Study Data
by Jon C. Ogg
24/7 Wall St.
Cell Genesys, Inc. (CEGE-NASDAQ) is trading up more than 7% at $5.50 in earlybird trading on thin volume this morning on its new prostate cancer studies. Yesterday it closed down at $5.10, more than $2.00 off its its highs over the last 5-days. It recently raised cash as well to continue funding for Phase III's, but here is the data they are releasing:
....reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer. In addition, the antibody responses to this non patient- specific product were predominantly patient-specific and unique from patient to patient, indicating the potential advantage of a cell-based multi-antigen product such as GVAX to generate the broadest and most relevant immune response. Serological analysis of gene expression (SEREX) technology was also used to identify target antigens involved in response to the immunotherapy. More than 148 proteins to which antibody responses were induced were identified and many of these proteins had not been identified previously as prostate cancer-associated antigens. These findings were presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the annual meeting of the American Association for Clinical Research being held in Los Angeles, CA.
Here is the full link to the press release.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Cell Genesys Climbs On GVAX Results
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
______________________
24/7 Wall St.
Cell Genesys, Inc. (CEGE-NASDAQ) is trading up more than 7% at $5.50 in earlybird trading on thin volume this morning on its new prostate cancer studies. Yesterday it closed down at $5.10, more than $2.00 off its its highs over the last 5-days. It recently raised cash as well to continue funding for Phase III's, but here is the data they are releasing:
....reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer. In addition, the antibody responses to this non patient- specific product were predominantly patient-specific and unique from patient to patient, indicating the potential advantage of a cell-based multi-antigen product such as GVAX to generate the broadest and most relevant immune response. Serological analysis of gene expression (SEREX) technology was also used to identify target antigens involved in response to the immunotherapy. More than 148 proteins to which antibody responses were induced were identified and many of these proteins had not been identified previously as prostate cancer-associated antigens. These findings were presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the annual meeting of the American Association for Clinical Research being held in Los Angeles, CA.
Here is the full link to the press release.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Cell Genesys Climbs On GVAX Results
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
______________________
posted by Nico at
8:14 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home